Tdap vac for repeat vaccination

March 7, 2019 0 By FM

The US FDA has approved the expanded use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed (Adacel) to include repeat vaccination to help protect against tetanus, diphtheria and pertussis. It is now the first and only Tdap vaccine in the US approved for a repeat dose in people 10 through 64 years of age 8 years or more after the first vaccination, Sanofi Pasteur said.
The FDA licensure was based on clinical data from a study of the safety and effectiveness of repeat vaccination in adults. In the study of more than 1,300 adults (aged 18 through 64 years), participants received either the vaccine or a tetanus-diphtheria (Td) vaccine 8-12 years after a previous dose of the vaccine.
The results of the study published in the Journal of the Pediatric Infectious Diseases Society showed a second dose of the
Tdap vaccine in adults administered 8-12 years after a previous dose found no significant differences in adverse events between vaccine groups.